The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Pharmacy benefits managers, or PBMs, are meant to act as a middleman between drug manufacturers and insurance companies, with ...

The Iowa legislation would require PBMs to reimburse pharmacies for the national or Iowa average acquisition drug costs.

Pharmacists are praising a bill under consideration in the Iowa House and Senate that would set new restrictions on pharmacy ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...